WallStreetZenWallStreetZen

NYSE: NVO
Novo Nordisk A S Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Novo Nordisk (Ozempic) earnings were $17.9B for the trailing 12 months ending Jun 30, 2026, with 2% growth year over year. The latest NVO earnings report on Jun 30, 2026 announced Q2 2026 earnings of $3.2B, down 57% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, NVO reported annual earnings of $16.1B, with 14.4% growth.

NVO past earnings growth

How has NVO's earnings growth performed historically?

Company
2.01%
Industry
15.67%
Market
89.83%
NVO's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
NVO's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
NVO's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

NVO earnings history

Current Revenue
$50.3B
Current Earnings
$17.8B
Current Profit Margin
35.3%
NVO's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

NVO Return on Equity

Current Company
59.1%
Current Industry
-6.9%
Current Market
29.1%
NVO's Return on Equity (59.1%)... subscribe to Premium to read more.
High Return on Equity Performance

NVO Return on Assets

Current Company
21.1%
Current Industry
-7%
NVO is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when NVO announces earnings.

NVO Return on Capital Employed

Current Company
41.8%
Current Industry
-1.4%
NVO's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

NVO vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
NVO$27.06B$17.91B+21.21%$4.04
VRTX$5.50B$4.41B+17.68%$17.33
UTHR$1.68B$1.31B+23.42%$30.24
REGN$5.75B$4.33B-6.56%$41.94
ARGX$2.03B$1.95B+26.02%$31.53
View Top Biotech Stocks

Novo Nordisk (Ozempic) Earnings Reports & History FAQ

What were Novo Nordisk (Ozempic)'s earnings last quarter?

On NVO's earnings call on Aug 5, 2026, Novo Nordisk (Ozempic) (NYSE: NVO) reported Q2 2026 earnings per share (EPS) of $0.72, up 22.73% year over year. Total NVO earnings for the quarter were $3.20 billion. In the same quarter last year, Novo Nordisk (Ozempic)'s earnings per share (EPS) was $0.94.

If you're new to stock investing, here's how to buy Novo Nordisk (Ozempic) stock.

Is Novo Nordisk (Ozempic) profitable or losing money?

As of the last Novo Nordisk (Ozempic) earnings report, Novo Nordisk (Ozempic) is currently profitable. Novo Nordisk (Ozempic)'s net profit (also called net income) for the twelve months ending Jun 30, 2026 was $17.78 billion, a 1.8% increase year over year.

What was NVO's earnings growth in the past year?

As of Novo Nordisk (Ozempic)'s earnings date in Aug 5, 2026, Novo Nordisk (Ozempic)'s earnings has grown 2.01% year over year. This is 13.66 percentage points lower than the US Biotechnology industry earnings growth rate of 15.67%. NVO earnings in the past year totalled $17.91 billion.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.